Uso de protetor gástrico associado a anti-inflamatórios não esteroidais em potros e equinos adultos

Abstract

The aim was to evaluate the effect on the gastric mucosa of the use of non-steroidal anti-inflammatory drugs phenylbutazone and firocoxib and the association with omeprazole in foals and adult horses. Twenty adult animals and 10 foals were evaluated. Adults were divided into 4 groups of 5 animals each: firocoxib (AFI, 0.1mg/kg, PO), firocoxib + omeprazole (AFIO, 4mg/kg, PO), phenylbutazone (APH, 4.4mg/kg, IV), phenylbutazone + omeprazole (APHO). The foals were divided into 2 groups of 5 animals each: phenylbutazone (FPH) and phenylbutazone + omeprazole (FPHO). Both categories received the treatment for 14 days. Gastroscopies were performed on days D0, D7, D14 and D21, and hematological and biochemical tests on days D0 and D21. In adults, an increase in the ulcer score was observed in animals that received phenylbutazone (APH) (60%) compared to the group that received firocoxib (AFI) (20%). In the group that received phenylbutazone and omeprazole (AFIO), none of the horses showed an increase in score. In the group that received phenylbutazone and omeprazole (APHO) 40% of the animals had worsening of the lesions, but without evolution to more severe scores. In the category of foals, there was no difference between the groups that received phenylbutazone alone or associated with omeprazole (FPH and FPHO). In this study, there was no difference in treatments for both adult animals and foals. However, in adult animals, the combined use of omeprazole with phenylbutazone and firocoxib suggested a protective effect on the evolution of ulcer scores. Alone, phenylbutazone induced more severe lesions when compared to firocoxib.